Watchlist Price Alert

Aurinia Pharmaceuticals I... (AUPH)

NASDAQ: AUPH · Real-Time Price · USD

8.18

0.03 (0.37%)

At close: May 16, 2025, 10:23 AM

0.37% (1D)

Bid	8.17
Market Cap	1.1B
Revenue (ttm)	247.29M
Net Income (ttm)	39.84M
EPS (ttm)	0.27
PE Ratio (ttm)	30.28
Forward PE	10.53
Analyst	Buy

Ask	8.18
Volume	274,824
Avg. Volume (20D)	1,443,130
Open	8.11
Previous Close	8.15
Day's Range	8.09 - 8.20
52-Week Range	5.11 - 10.67
Beta	1.17

About AUPH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AUPH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AUPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Aurinia Pharmaceuticals has released their quartely earnings on May 12, 2025:

Revenue of $62.47M exceeds estimates by $1.41M, with 24.18% YoY growth.

EPS of 0.16 exceeds estimates by 0.06, with 328.57% YoY growth.

Why Price Moved

6 months ago

+10.9%

Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

8 months ago

+0.77%

Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.

News

4 days ago · benzinga.com

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.

4 days ago · seekingalpha.com

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - Preside...

3 days ago · zacks.com

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.

3 days ago · businesswire.com

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.

1 week ago · businesswire.com

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.

2 weeks ago · businesswire.com

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.

2 weeks ago · businesswire.com

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.

2 weeks ago · seekingalpha.com

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 ear...

3 weeks ago · zacks.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

2 months ago · 247wallst.com

Insiders Are Loading Up on These 4 Biotech Stocks Now

Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.

Load More News